Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions
- 4 May 2004
- journal article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 30 (5) , 540-545
- https://doi.org/10.1111/j.1365-2990.2004.00561.x
Abstract
Immunohistochemistry using antibodies to dystrophin is the pathological basis for the diagnosis of Duchenne and Becker muscular dystrophy (DMD and BMD). While the sarcolemma of DMD muscle is negative, BMD muscle generally shows variable labelling because of the translation of a partially functional dystrophin that is localized to the sarcolemma. In rare cases, however, this labelling is equivocal and similar to that observed in controls making diagnosis difficult. We report here that in such instances immunolabelling with antibodies to the neuronal form of nitric oxide synthase (nNOS) can be useful in suspecting a dystrophinopathy with a mutation in the ‘hot‐spot’ rod domain and help to direct molecular analysis. nNOS localizes to the sarcolemma of mature muscle fibres via several components of the dystrophin‐associated protein complex (DAPC) including dystrophin but sarcolemmal nNOS is lost when dystrophin levels are very low or absent because of deletions in critical regions of the rod domain. We report three cases who presented with only mild or no muscle weakness but had elevated serum creatine kinase activity and dystrophin immunolabelling indistinguishable from normal, making a pathological diagnosis difficult. All three cases had a complete absence of sarcolemmal nNOS and were subsequently found to have an in‐frame deletion in the common rod domain exons (in these cases 48, 45–51, 47–53) compatible with a BMD. In addition, we observed that nNOS appears to be developmentally regulated with the antibody used and was often absent from the sarcolemma of immature fibres. These findings demonstrate the value of including antibodies to nNOS in routine immunohistochemical studies and that absence of nNOS can be a more sensitive marker than up‐regulation of utrophin for diagnosis of BMD. Immaturity of fibres, however, needs to be taken into account, especially in neonates.Keywords
This publication has 14 references indexed in Scilit:
- Loss of sarcolemma nNOS in sarcoglycan‐deficient muscleThe FASEB Journal, 2002
- The abnormal expression of utrophin in Duchenne and Becker muscular dystrophy is age relatedNeuropathology and Applied Neurobiology, 1997
- The abnormal expression of utrophin in Duchenne and Becker muscular dystrophy is age relatedNeuropathology and Applied Neurobiology, 1997
- Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy.The Journal of Experimental Medicine, 1996
- Interaction of Nitric Oxide Synthase with the Postsynaptic Density Protein PSD-95 and α1-Syntrophin Mediated by PDZ DomainsPublished by Elsevier ,1996
- Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophyCell, 1995
- Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Detection of 98% of DMD/BMD gene deletions by polymerase chain reactionHuman Genetics, 1990
- Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplificationNucleic Acids Research, 1988
- An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locusGenomics, 1988